Anti-CD79a Cocktail, clone JCB117 + HM47/A9

0.2 mg/ml with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide. A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. CD79a antibody is generally used to complement CD20 antibody especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody cocktail will stain many of the same lymphomas as CD20 antibody, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is CD20 antibody. CD79a antibody also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well. Protein function: Required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src- family tyrosine kinases. Represses BCR signaling during development of immature B-cells. [The UniProt Consortium]